Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Free Cash Flow (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Free Cash Flow for 11 consecutive years, with -$14.7 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 62.08% to -$14.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $865000.0 through Dec 2025, up 100.58% year-over-year, with the annual reading at $865000.0 for FY2025, 100.58% up from the prior year.
  • Free Cash Flow hit -$14.7 million in Q4 2025 for Seres Therapeutics, down from $2.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $128.0 million in Q3 2021 to a low of -$77.5 million in Q1 2023.
  • Historically, Free Cash Flow has averaged -$25.4 million across 5 years, with a median of -$38.9 million in 2021.
  • Biggest YoY gain for Free Cash Flow was 593.72% in 2021; the steepest drop was 236.66% in 2021.
  • Year by year, Free Cash Flow stood at -$61.1 million in 2021, then grew by 11.46% to -$54.1 million in 2022, then decreased by 1.84% to -$55.1 million in 2023, then grew by 29.46% to -$38.9 million in 2024, then surged by 62.08% to -$14.7 million in 2025.
  • Business Quant data shows Free Cash Flow for MCRB at -$14.7 million in Q4 2025, $2.2 million in Q3 2025, and -$13.5 million in Q2 2025.